Panobinostat [clinicaltrials_resource:e118b8699b16aa881c3d2b01900342ca]
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma [clinicaltrials:NCT00412997]Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone [clinicaltrials:NCT00419536]clinicaltrials:NCT00425555Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma [clinicaltrials:NCT00445068]Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis) [clinicaltrials:NCT00449761]Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase [clinicaltrials:NCT00451035]A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 [clinicaltrials:NCT00472368]Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma [clinicaltrials:NCT00490776]Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone [clinicaltrials:NCT00493766]A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors [clinicaltrials:NCT00503451]clinicaltrials:NCT00532389clinicaltrials:NCT00532675Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma [clinicaltrials:NCT00535951]LBH589 and Gemcitabine in the Treatment of Solid Tumors [clinicaltrials:NCT00550199]clinicaltrials:NCT00550277LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors [clinicaltrials:NCT00556088]clinicaltrials:NCT00567879A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors [clinicaltrials:NCT00570284]clinicaltrials:NCT00594230A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies [clinicaltrials:NCT00621244]clinicaltrials:NCT00632489A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer [clinicaltrials:NCT00663832]Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer [clinicaltrials:NCT00667862]A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer [clinicaltrials:NCT00670553]clinicaltrials:NCT00686218Phase II Trial of LBH589 in Refractory Colorectal Cancer [clinicaltrials:NCT00690677]clinicaltrials:NCT00691938Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma [clinicaltrials:NCT00699296]clinicaltrials:NCT00723203clinicaltrials:NCT00738751Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors [clinicaltrials:NCT00739414]clinicaltrials:NCT00742027clinicaltrials:NCT00743288Study of Panobinostat Monotherapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer [clinicaltrials:NCT00777049]clinicaltrials:NCT00777335A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer [clinicaltrials:NCT00788931]Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) [clinicaltrials:NCT00823290]clinicaltrials:NCT00840346Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors [clinicaltrials:NCT00848523]clinicaltrials:NCT00859222
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Panobinostat [clinicaltrials_resource:e118b8699b16aa881c3d2b01900342ca]
Bio2RDF identifier
e118b8699b16aa881c3d2b01900342ca
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e118b8699b16aa881c3d2b01900342ca
identifier
clinicaltrials_resource:e118b8699b16aa881c3d2b01900342ca
title
Panobinostat
@en
type
label
Panobinostat [clinicaltrials_resource:e118b8699b16aa881c3d2b01900342ca]
@en